<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37524529</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>101</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Amyotrophic Lateral Sclerosis Quality Measurement Set 2022 Update: Quality Improvement in Neurology.</ArticleTitle><Pagination><StartPage>223</StartPage><EndPage>232</EndPage><MedlinePgn>223-232</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000207166</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kvam</LastName><ForeName>Kathryn A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Neurological Sciences (K.A.K.), Stanford University, Palo Alto, CA; Department of Neurology (M.B.), Leonard M. Miller School of Medicine, University of Miami, FL; The ALS Association (A.B., J.R.), Washington, DC; Cheyenne Regional Medical Group (T.C.), WY; Department of Neurology (R.R.D.), UT Southwestern Medical Center, Dallas, TX; I AM ALS (P.G., N.S.), Washington, DC; Crestwood ALS Care Clinic (S.K.), Huntsville, AL; Sean M. Healey &amp; AMG Center for ALS (D.S.), Massachusetts General Hospital, Boston; Department of Neurology (K.S.), Warren Alpert Medical School of Brown University, Providence, RI; Mayo Clinic (J.S.), Rochester, MN; Academy of Nutrition and Dietetics (N.G.W.), Chicago, IL; American Academy of Neurology (A.B., S.R.W.), Minneapolis, MN; and Department of Neurology (B.R.B.), Carolinas Medical Center, University of North Carolina School of Medicine, Charlotte.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benatar</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Neurological Sciences (K.A.K.), Stanford University, Palo Alto, CA; Department of Neurology (M.B.), Leonard M. Miller School of Medicine, University of Miami, FL; The ALS Association (A.B., J.R.), Washington, DC; Cheyenne Regional Medical Group (T.C.), WY; Department of Neurology (R.R.D.), UT Southwestern Medical Center, Dallas, TX; I AM ALS (P.G., N.S.), Washington, DC; Crestwood ALS Care Clinic (S.K.), Huntsville, AL; Sean M. Healey &amp; AMG Center for ALS (D.S.), Massachusetts General Hospital, Boston; Department of Neurology (K.S.), Warren Alpert Medical School of Brown University, Providence, RI; Mayo Clinic (J.S.), Rochester, MN; Academy of Nutrition and Dietetics (N.G.W.), Chicago, IL; American Academy of Neurology (A.B., S.R.W.), Minneapolis, MN; and Department of Neurology (B.R.B.), Carolinas Medical Center, University of North Carolina School of Medicine, Charlotte.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brownlee</LastName><ForeName>Alisa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Neurological Sciences (K.A.K.), Stanford University, Palo Alto, CA; Department of Neurology (M.B.), Leonard M. Miller School of Medicine, University of Miami, FL; The ALS Association (A.B., J.R.), Washington, DC; Cheyenne Regional Medical Group (T.C.), WY; Department of Neurology (R.R.D.), UT Southwestern Medical Center, Dallas, TX; I AM ALS (P.G., N.S.), Washington, DC; Crestwood ALS Care Clinic (S.K.), Huntsville, AL; Sean M. Healey &amp; AMG Center for ALS (D.S.), Massachusetts General Hospital, Boston; Department of Neurology (K.S.), Warren Alpert Medical School of Brown University, Providence, RI; Mayo Clinic (J.S.), Rochester, MN; Academy of Nutrition and Dietetics (N.G.W.), Chicago, IL; American Academy of Neurology (A.B., S.R.W.), Minneapolis, MN; and Department of Neurology (B.R.B.), Carolinas Medical Center, University of North Carolina School of Medicine, Charlotte.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caller</LastName><ForeName>Tracie</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Neurological Sciences (K.A.K.), Stanford University, Palo Alto, CA; Department of Neurology (M.B.), Leonard M. Miller School of Medicine, University of Miami, FL; The ALS Association (A.B., J.R.), Washington, DC; Cheyenne Regional Medical Group (T.C.), WY; Department of Neurology (R.R.D.), UT Southwestern Medical Center, Dallas, TX; I AM ALS (P.G., N.S.), Washington, DC; Crestwood ALS Care Clinic (S.K.), Huntsville, AL; Sean M. Healey &amp; AMG Center for ALS (D.S.), Massachusetts General Hospital, Boston; Department of Neurology (K.S.), Warren Alpert Medical School of Brown University, Providence, RI; Mayo Clinic (J.S.), Rochester, MN; Academy of Nutrition and Dietetics (N.G.W.), Chicago, IL; American Academy of Neurology (A.B., S.R.W.), Minneapolis, MN; and Department of Neurology (B.R.B.), Carolinas Medical Center, University of North Carolina School of Medicine, Charlotte.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Das</LastName><ForeName>Rohit R</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Neurological Sciences (K.A.K.), Stanford University, Palo Alto, CA; Department of Neurology (M.B.), Leonard M. Miller School of Medicine, University of Miami, FL; The ALS Association (A.B., J.R.), Washington, DC; Cheyenne Regional Medical Group (T.C.), WY; Department of Neurology (R.R.D.), UT Southwestern Medical Center, Dallas, TX; I AM ALS (P.G., N.S.), Washington, DC; Crestwood ALS Care Clinic (S.K.), Huntsville, AL; Sean M. Healey &amp; AMG Center for ALS (D.S.), Massachusetts General Hospital, Boston; Department of Neurology (K.S.), Warren Alpert Medical School of Brown University, Providence, RI; Mayo Clinic (J.S.), Rochester, MN; Academy of Nutrition and Dietetics (N.G.W.), Chicago, IL; American Academy of Neurology (A.B., S.R.W.), Minneapolis, MN; and Department of Neurology (B.R.B.), Carolinas Medical Center, University of North Carolina School of Medicine, Charlotte.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Phil</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Neurological Sciences (K.A.K.), Stanford University, Palo Alto, CA; Department of Neurology (M.B.), Leonard M. Miller School of Medicine, University of Miami, FL; The ALS Association (A.B., J.R.), Washington, DC; Cheyenne Regional Medical Group (T.C.), WY; Department of Neurology (R.R.D.), UT Southwestern Medical Center, Dallas, TX; I AM ALS (P.G., N.S.), Washington, DC; Crestwood ALS Care Clinic (S.K.), Huntsville, AL; Sean M. Healey &amp; AMG Center for ALS (D.S.), Massachusetts General Hospital, Boston; Department of Neurology (K.S.), Warren Alpert Medical School of Brown University, Providence, RI; Mayo Clinic (J.S.), Rochester, MN; Academy of Nutrition and Dietetics (N.G.W.), Chicago, IL; American Academy of Neurology (A.B., S.R.W.), Minneapolis, MN; and Department of Neurology (B.R.B.), Carolinas Medical Center, University of North Carolina School of Medicine, Charlotte.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kolodziejczak</LastName><ForeName>Sherry</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Neurological Sciences (K.A.K.), Stanford University, Palo Alto, CA; Department of Neurology (M.B.), Leonard M. Miller School of Medicine, University of Miami, FL; The ALS Association (A.B., J.R.), Washington, DC; Cheyenne Regional Medical Group (T.C.), WY; Department of Neurology (R.R.D.), UT Southwestern Medical Center, Dallas, TX; I AM ALS (P.G., N.S.), Washington, DC; Crestwood ALS Care Clinic (S.K.), Huntsville, AL; Sean M. Healey &amp; AMG Center for ALS (D.S.), Massachusetts General Hospital, Boston; Department of Neurology (K.S.), Warren Alpert Medical School of Brown University, Providence, RI; Mayo Clinic (J.S.), Rochester, MN; Academy of Nutrition and Dietetics (N.G.W.), Chicago, IL; American Academy of Neurology (A.B., S.R.W.), Minneapolis, MN; and Department of Neurology (B.R.B.), Carolinas Medical Center, University of North Carolina School of Medicine, Charlotte.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russo</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Neurological Sciences (K.A.K.), Stanford University, Palo Alto, CA; Department of Neurology (M.B.), Leonard M. Miller School of Medicine, University of Miami, FL; The ALS Association (A.B., J.R.), Washington, DC; Cheyenne Regional Medical Group (T.C.), WY; Department of Neurology (R.R.D.), UT Southwestern Medical Center, Dallas, TX; I AM ALS (P.G., N.S.), Washington, DC; Crestwood ALS Care Clinic (S.K.), Huntsville, AL; Sean M. Healey &amp; AMG Center for ALS (D.S.), Massachusetts General Hospital, Boston; Department of Neurology (K.S.), Warren Alpert Medical School of Brown University, Providence, RI; Mayo Clinic (J.S.), Rochester, MN; Academy of Nutrition and Dietetics (N.G.W.), Chicago, IL; American Academy of Neurology (A.B., S.R.W.), Minneapolis, MN; and Department of Neurology (B.R.B.), Carolinas Medical Center, University of North Carolina School of Medicine, Charlotte.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanders</LastName><ForeName>Danica</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Neurological Sciences (K.A.K.), Stanford University, Palo Alto, CA; Department of Neurology (M.B.), Leonard M. Miller School of Medicine, University of Miami, FL; The ALS Association (A.B., J.R.), Washington, DC; Cheyenne Regional Medical Group (T.C.), WY; Department of Neurology (R.R.D.), UT Southwestern Medical Center, Dallas, TX; I AM ALS (P.G., N.S.), Washington, DC; Crestwood ALS Care Clinic (S.K.), Huntsville, AL; Sean M. Healey &amp; AMG Center for ALS (D.S.), Massachusetts General Hospital, Boston; Department of Neurology (K.S.), Warren Alpert Medical School of Brown University, Providence, RI; Mayo Clinic (J.S.), Rochester, MN; Academy of Nutrition and Dietetics (N.G.W.), Chicago, IL; American Academy of Neurology (A.B., S.R.W.), Minneapolis, MN; and Department of Neurology (B.R.B.), Carolinas Medical Center, University of North Carolina School of Medicine, Charlotte.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sethi</LastName><ForeName>Nadia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Neurological Sciences (K.A.K.), Stanford University, Palo Alto, CA; Department of Neurology (M.B.), Leonard M. Miller School of Medicine, University of Miami, FL; The ALS Association (A.B., J.R.), Washington, DC; Cheyenne Regional Medical Group (T.C.), WY; Department of Neurology (R.R.D.), UT Southwestern Medical Center, Dallas, TX; I AM ALS (P.G., N.S.), Washington, DC; Crestwood ALS Care Clinic (S.K.), Huntsville, AL; Sean M. Healey &amp; AMG Center for ALS (D.S.), Massachusetts General Hospital, Boston; Department of Neurology (K.S.), Warren Alpert Medical School of Brown University, Providence, RI; Mayo Clinic (J.S.), Rochester, MN; Academy of Nutrition and Dietetics (N.G.W.), Chicago, IL; American Academy of Neurology (A.B., S.R.W.), Minneapolis, MN; and Department of Neurology (B.R.B.), Carolinas Medical Center, University of North Carolina School of Medicine, Charlotte.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stavros</LastName><ForeName>Kara</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Neurological Sciences (K.A.K.), Stanford University, Palo Alto, CA; Department of Neurology (M.B.), Leonard M. Miller School of Medicine, University of Miami, FL; The ALS Association (A.B., J.R.), Washington, DC; Cheyenne Regional Medical Group (T.C.), WY; Department of Neurology (R.R.D.), UT Southwestern Medical Center, Dallas, TX; I AM ALS (P.G., N.S.), Washington, DC; Crestwood ALS Care Clinic (S.K.), Huntsville, AL; Sean M. Healey &amp; AMG Center for ALS (D.S.), Massachusetts General Hospital, Boston; Department of Neurology (K.S.), Warren Alpert Medical School of Brown University, Providence, RI; Mayo Clinic (J.S.), Rochester, MN; Academy of Nutrition and Dietetics (N.G.W.), Chicago, IL; American Academy of Neurology (A.B., S.R.W.), Minneapolis, MN; and Department of Neurology (B.R.B.), Carolinas Medical Center, University of North Carolina School of Medicine, Charlotte.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stierwalt</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Neurological Sciences (K.A.K.), Stanford University, Palo Alto, CA; Department of Neurology (M.B.), Leonard M. Miller School of Medicine, University of Miami, FL; The ALS Association (A.B., J.R.), Washington, DC; Cheyenne Regional Medical Group (T.C.), WY; Department of Neurology (R.R.D.), UT Southwestern Medical Center, Dallas, TX; I AM ALS (P.G., N.S.), Washington, DC; Crestwood ALS Care Clinic (S.K.), Huntsville, AL; Sean M. Healey &amp; AMG Center for ALS (D.S.), Massachusetts General Hospital, Boston; Department of Neurology (K.S.), Warren Alpert Medical School of Brown University, Providence, RI; Mayo Clinic (J.S.), Rochester, MN; Academy of Nutrition and Dietetics (N.G.W.), Chicago, IL; American Academy of Neurology (A.B., S.R.W.), Minneapolis, MN; and Department of Neurology (B.R.B.), Carolinas Medical Center, University of North Carolina School of Medicine, Charlotte.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giles Walters</LastName><ForeName>Nancy</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Neurological Sciences (K.A.K.), Stanford University, Palo Alto, CA; Department of Neurology (M.B.), Leonard M. Miller School of Medicine, University of Miami, FL; The ALS Association (A.B., J.R.), Washington, DC; Cheyenne Regional Medical Group (T.C.), WY; Department of Neurology (R.R.D.), UT Southwestern Medical Center, Dallas, TX; I AM ALS (P.G., N.S.), Washington, DC; Crestwood ALS Care Clinic (S.K.), Huntsville, AL; Sean M. Healey &amp; AMG Center for ALS (D.S.), Massachusetts General Hospital, Boston; Department of Neurology (K.S.), Warren Alpert Medical School of Brown University, Providence, RI; Mayo Clinic (J.S.), Rochester, MN; Academy of Nutrition and Dietetics (N.G.W.), Chicago, IL; American Academy of Neurology (A.B., S.R.W.), Minneapolis, MN; and Department of Neurology (B.R.B.), Carolinas Medical Center, University of North Carolina School of Medicine, Charlotte.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Neurological Sciences (K.A.K.), Stanford University, Palo Alto, CA; Department of Neurology (M.B.), Leonard M. Miller School of Medicine, University of Miami, FL; The ALS Association (A.B., J.R.), Washington, DC; Cheyenne Regional Medical Group (T.C.), WY; Department of Neurology (R.R.D.), UT Southwestern Medical Center, Dallas, TX; I AM ALS (P.G., N.S.), Washington, DC; Crestwood ALS Care Clinic (S.K.), Huntsville, AL; Sean M. Healey &amp; AMG Center for ALS (D.S.), Massachusetts General Hospital, Boston; Department of Neurology (K.S.), Warren Alpert Medical School of Brown University, Providence, RI; Mayo Clinic (J.S.), Rochester, MN; Academy of Nutrition and Dietetics (N.G.W.), Chicago, IL; American Academy of Neurology (A.B., S.R.W.), Minneapolis, MN; and Department of Neurology (B.R.B.), Carolinas Medical Center, University of North Carolina School of Medicine, Charlotte.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wessels</LastName><ForeName>Scott R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Neurological Sciences (K.A.K.), Stanford University, Palo Alto, CA; Department of Neurology (M.B.), Leonard M. Miller School of Medicine, University of Miami, FL; The ALS Association (A.B., J.R.), Washington, DC; Cheyenne Regional Medical Group (T.C.), WY; Department of Neurology (R.R.D.), UT Southwestern Medical Center, Dallas, TX; I AM ALS (P.G., N.S.), Washington, DC; Crestwood ALS Care Clinic (S.K.), Huntsville, AL; Sean M. Healey &amp; AMG Center for ALS (D.S.), Massachusetts General Hospital, Boston; Department of Neurology (K.S.), Warren Alpert Medical School of Brown University, Providence, RI; Mayo Clinic (J.S.), Rochester, MN; Academy of Nutrition and Dietetics (N.G.W.), Chicago, IL; American Academy of Neurology (A.B., S.R.W.), Minneapolis, MN; and Department of Neurology (B.R.B.), Carolinas Medical Center, University of North Carolina School of Medicine, Charlotte.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brooks</LastName><ForeName>Benjamin Rix</ForeName><Initials>BR</Initials><Identifier Source="ORCID">0000-0002-1914-5061</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology and Neurological Sciences (K.A.K.), Stanford University, Palo Alto, CA; Department of Neurology (M.B.), Leonard M. Miller School of Medicine, University of Miami, FL; The ALS Association (A.B., J.R.), Washington, DC; Cheyenne Regional Medical Group (T.C.), WY; Department of Neurology (R.R.D.), UT Southwestern Medical Center, Dallas, TX; I AM ALS (P.G., N.S.), Washington, DC; Crestwood ALS Care Clinic (S.K.), Huntsville, AL; Sean M. Healey &amp; AMG Center for ALS (D.S.), Massachusetts General Hospital, Boston; Department of Neurology (K.S.), Warren Alpert Medical School of Brown University, Providence, RI; Mayo Clinic (J.S.), Rochester, MN; Academy of Nutrition and Dietetics (N.G.W.), Chicago, IL; American Academy of Neurology (A.B., S.R.W.), Minneapolis, MN; and Department of Neurology (B.R.B.), Carolinas Medical Center, University of North Carolina School of Medicine, Charlotte.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058996" MajorTopicYN="N">Quality Improvement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009462" MajorTopicYN="Y">Neurology</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>K.A. Kvam has received personal compensation for serving as Deputy Editor of <i>Neurology Clinical Practice</i>. M. Benatar has received personal compensation in the range of $10,000-$49,999 for serving as a consultant for Biogen, personal compensation in the range of $500-$4,999 for serving as a consultant for Jazz Pharmaceuticals, personal compensation in the range of $10,000-$49,999 for serving as a consultant for Alexion, personal compensation in the range of $500-$4,999 for serving as a consultant for Annexon, personal compensation in the range of $500-$4,999 for serving as a consultant for UCB, personal compensation in the range of $500-$4,999 for serving as a consultant for UniQure, personal compensation in the range of $5,000-$9,999 for serving as a consultant for Immunovant, personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SwanBio, personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Denali, personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alector, personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi, personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis, and intellectual property interests from a discovery or technology relating to health care. The institution of Dr. Benatar has received personal compensation in the range of $5,000-$9,999 for serving as a consultant for Arrowhead. A. Brownlee has received personal compensation for serving as an employee of RESNA. T. Caller has no disclosures to report. R.D. Das has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Janicek. The institution of an immediate family member of Dr. Das has received research support from the NIH. P. Green, S. Kolodziejczak, J. Russo, and D. Sanders have no disclosures to report. N. Sethi has received personal compensation for serving as an employee of ALS TDI, personal compensation in the range of $500-$4,999 for serving as a consultant for Cytokinetics, personal compensation in the range of $500-$4,999 for serving as a consultant for IONIS Pharmaceuticals, personal compensation in the range of $500-$4,999 for serving as a consultant for Biogen, and personal compensation in the range of $500-$4,999 for serving as a consultant for Merck. K. Stavros has no disclosures to report. J. Stierwalt has received research support from the NIH and publishing royalties from a publication relating to health care. The institution of Julie Stierwalt has received research support from the NIH. N. Giles Walters has no disclosures to report. A. Bennett and S.R. Wessels are employees of the American Academy of Neurology. B. R. Brooks has received personal compensation in the range of $500-$4,999 for serving as a consultant for ITF Pharma, personal compensation in the range of $500-$4,999 for serving as a consultant for Mitsubishi Tanabe Pharma America, personal compensation in the range of $5,000-$9,999 for serving as a consultant for MediciNova, personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen, personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AB Science, personal compensation in the range of $500-$4,999 for serving on a speakers bureau for Mitsubishi Tanabe Pharma America, personal compensation in the range of $5,000-$9,999 for serving on a speakers bureau for Cytokinetics, research support from Alexion, and personal compensation in the range of $0-$499 for serving as a Member Annual Surveillance Committee CDC National ALS Registry with Center for Disease Control Agency Toxic Substances Disease Registry and has a noncompensated relationship as a Member ALS Quality Measures Subcommittee with American Academy of Neurology that is relevant to AAN interests or activities. The institution of Dr. Brooks has received research support from Orion, Mitsubishi Tanabe Pharma America, and Biohaven. Go to Neurology.org/N for full disclosures.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>1</Day><Hour>1</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>31</Day><Hour>21</Hour><Minute>39</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37524529</ArticleId><ArticleId IdType="pmc">PMC10401684</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000207166</ArticleId><ArticleId IdType="pii">101/5/223</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mehta P, Raymond J, Punjani R, et al. . Prevalence of amyotrophic lateral sclerosis (ALS), United States, 2016. Amyotroph Lateral Scler Frontotemporal Degener. 2022;23(3-4):220-225. doi:10.1080/21678421.2021.1949021</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2021.1949021</ArticleId><ArticleId IdType="pubmed">34423697</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson LM, Topol B, Kaye W, et al. . Evaluation of the completeness of ALS case ascertainment in the US national ALS Registry: application of the capture-recapture method. Neuroepidemiology. 2022;56(2):104-114. doi:10.1159/000521591</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000521591</ArticleId><ArticleId IdType="pubmed">34929703</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, Liu T, Liu L, et al. . Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol. 2020;267(4):944-953. doi:10.1007/s00415-019-09652-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09652-y</ArticleId><ArticleId IdType="pubmed">31797084</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng HJ, Debray TPA, Visser AE, et al. . Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17(5):423-433. doi:10.1016/s1474-4422(18)30089-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1474-4422(18)30089-9</ArticleId><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo L, Song Z, Li X, et al. . Efficacy and safety of edaravone in treatment of amyotrophic lateral sclerosis-a systematic review and meta-analysis. Neurol Sci. 2019;40(2):235-241. doi:10.1007/s10072-018-3653-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-018-3653-2</ArticleId><ArticleId IdType="pubmed">30483992</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong C, Stavrou M, Elliott E, et al. . Clinical trials in amyotrophic lateral sclerosis: a systematic review and perspective. Brain Commun. 2021;3(4):fcab242. doi:10.1093/braincomms/fcab242</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcab242</ArticleId><ArticleId IdType="pmc">PMC8659356</ArticleId><ArticleId IdType="pubmed">34901853</ArticleId></ArticleIdList></Reference><Reference><Citation>Amado DA, Davidson BL. Gene therapy for ALS: a review. Mol Ther. 2021;29(12):3345-3358. doi:10.1016/j.ymthe.2021.04.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2021.04.008</ArticleId><ArticleId IdType="pmc">PMC8636154</ArticleId><ArticleId IdType="pubmed">33839324</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Brooks BR, Swain-Eng RJ, et al. . Quality improvement in neurology: amyotrophic lateral sclerosis quality measures: report of the quality measurement and reporting subcommittee of the American Academy of Neurology. Neurology. 2013;81(24):2136-2140. doi:10.1212/01.wnl.0000437305.37850.f9</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000437305.37850.f9</ArticleId><ArticleId IdType="pmc">PMC3863352</ArticleId><ArticleId IdType="pubmed">24271651</ArticleId></ArticleIdList></Reference><Reference><Citation>Brizzi KT, Bridges JFP, Yersak J, et al. . Understanding the needs of people with ALS: a national survey of patients and caregivers. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(5-6):355-363. doi:10.1080/21678421.2020.1760889</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1760889</ArticleId><ArticleId IdType="pubmed">32396393</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Anderson F, Brooks BR, Mitsumoto H, Bradley WG, Ringel SP. Outcomes research in amyotrophic lateral sclerosis: lessons learned from the amyotrophic lateral sclerosis clinical assessment, research, and education database. Ann Neurol. 2009;65(S1):S24-S28. doi:10.1002/ana.21556</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21556</ArticleId><ArticleId IdType="pubmed">19191307</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin B, Beghi E, Vial C, et al. . Evaluation of the application of the European guidelines for the diagnosis and clinical care of amyotrophic lateral sclerosis (ALS) patients in six French ALS centres. Eur J Neurol. 2016;23(4):787-795. doi:10.1111/ene.12941</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12941</ArticleId><ArticleId IdType="pubmed">26833536</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoesmith C, Abrahao A, Benstead T, et al. . Canadian best practice recommendations for the management of amyotrophic lateral sclerosis. CMAJ. 2020;192(46):E1453-E1468. doi:10.1503/cmaj.191721</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.191721</ArticleId><ArticleId IdType="pmc">PMC7683000</ArticleId><ArticleId IdType="pubmed">33199452</ArticleId></ArticleIdList></Reference><Reference><Citation>Motor Neurone Disease: Assessment and Management. 2016.</Citation></Reference><Reference><Citation>Pattee GL, Plowman EK, Focht Garand KL, et al. . Provisional best practices guidelines for the evaluation of bulbar dysfunction in amyotrophic lateral sclerosis. Muscle Nerve. 2019;59(5):531-536. doi:10.1002/mus.26408</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26408</ArticleId><ArticleId IdType="pubmed">30620104</ArticleId></ArticleIdList></Reference><Reference><Citation>Rimmer KP, Kaminska M, Nonoyama M, et al. . Home mechanical ventilation for patients with amyotrophic lateral sclerosis: a Canadian Thoracic Society clinical practice guideline. Can J Respir Crit Care Sleep Med. 2019;3(1):9-27. doi:10.1080/24745332.2018.1559644</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/24745332.2018.1559644</ArticleId></ArticleIdList></Reference><Reference><Citation>Georges M, Perez T, Rabec C, et al. . Proposals from a French expert panel for respiratory care in ALS patients. Respir Med Res. 2022;81:100901. doi:10.1016/j.resmer.2022.100901</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resmer.2022.100901</ArticleId><ArticleId IdType="pubmed">35378353</ArticleId></ArticleIdList></Reference><Reference><Citation>Martello J, Buchhalter J, Das RR, Dubinsky R, Lee E, Anderson W. Quality improvement in neurology: universal neurology quality measurement set: executive summary. Neurology. 2019;92(9):418-426. doi:10.1212/wnl.0000000000006927</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0000000000006927</ArticleId><ArticleId IdType="pubmed">30709967</ArticleId></ArticleIdList></Reference><Reference><Citation>Subcommittee QM. Quality measurement manual 2022 update. Accessed June 8. aan.com/siteassets/home-page/policy-and-guidelines/quality/quality-measures/how-measures-are-developed/22measuredevprocman.pdf.</Citation></Reference><Reference><Citation>Geronimo A, Wright C, Morris A, Walsh S, Snyder B, Simmons Z. Incorporation of telehealth into a multidisciplinary ALS Clinic: feasibility and acceptability. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(7-8):555-561. doi:10.1080/21678421.2017.1338298</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1338298</ArticleId><ArticleId IdType="pubmed">28678542</ArticleId></ArticleIdList></Reference><Reference><Citation>Helleman J, Kruitwagen ET, van den Berg LH, Visser-Meily JMA, Beelen A. The current use of telehealth in ALS care and the barriers to and facilitators of implementation: a systematic review. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(3-4):167-182. doi:10.1080/21678421.2019.1706581</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1706581</ArticleId><ArticleId IdType="pubmed">31878794</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkirk SM, Washington MO, McClellan F, Flynn B, Seton JM, Strozewski R. Delivering tertiary centre specialty care to ALS patients via telemedicine: a retrospective cohort analysis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(5-6):324-332. doi:10.1080/21678421.2017.1313867</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1313867</ArticleId><ArticleId IdType="pubmed">28427284</ArticleId></ArticleIdList></Reference><Reference><Citation>Giri PC, Stevens GJ, Merrill-Henry J, Oyoyo U, Balasubramanian VP. Participation in pulmonary hypertension support group improves patient-reported health quality outcomes: a patient and caregiver survey. Pulm Circ. 2021;11(2):1-11. doi:10.1177/20458940211013258</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20458940211013258</ArticleId><ArticleId IdType="pmc">PMC8132099</ArticleId><ArticleId IdType="pubmed">34035896</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad M, Genuis SK, Luth W, Bubela T, Johnston WS. Amyotrophic lateral sclerosis (ALS) health charities are central to ALS care: perspectives of Canadians affected by ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2022:1-10. doi:10.1080/21678421.2022.2119869</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2022.2119869</ArticleId><ArticleId IdType="pubmed">36111949</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordesse V, Sidorok F, Schimmel P, Holstein J, Meininger V. Coordinated care affects hospitalization and prognosis in amyotrophic lateral sclerosis: a cohort study. BMC Health Serv Res. 2015;15(1):134. doi:10.1186/s12913-015-0810-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12913-015-0810-7</ArticleId><ArticleId IdType="pmc">PMC4384378</ArticleId><ArticleId IdType="pubmed">25890266</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein LH, Atkins L, Landau S, Brown R, Leigh PN. Predictors of psychological distress in carers of people with amyotrophic lateral sclerosis: a longitudinal study. Psychol Med. 2006;36(6):865-875. doi:10.1017/s0033291706007124</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/s0033291706007124</ArticleId><ArticleId IdType="pubmed">16490122</ArticleId></ArticleIdList></Reference><Reference><Citation>Finger S. The family support group in the treatment of amyotrophic lateral sclerosis. Neurol Clin. 1987;5(1):83-100. doi:10.1016/s0733-8619(18)30936-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0733-8619(18)30936-8</ArticleId><ArticleId IdType="pubmed">3561383</ArticleId></ArticleIdList></Reference><Reference><Citation>Cipolletta S, Gammino GR, Francescon P, Palmieri A. Mutual support groups for family caregivers of people with amyotrophic lateral sclerosis in Italy: a pilot study. Health Soc Care Community. 2018;26(4):556-563. doi:10.1111/hsc.12558</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hsc.12558</ArticleId><ArticleId IdType="pubmed">29479773</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Jackson CE, Kasarskis EJ, et al. . Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73(15):1218-1226. doi:10.1212/wnl.0b013e3181bc0141</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0b013e3181bc0141</ArticleId><ArticleId IdType="pmc">PMC2764727</ArticleId><ArticleId IdType="pubmed">19822872</ArticleId></ArticleIdList></Reference><Reference><Citation>EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis; Andersen PM, Abrahams S, Borasio GD, et al. . EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force. Eur J Neurol. 2012;19(3):360-375. doi:10.1111/j.1468-1331.2011.03501.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2011.03501.x</ArticleId><ArticleId IdType="pubmed">21914052</ArticleId></ArticleIdList></Reference><Reference><Citation>Japan Society of Neurology. ALS Clinical Practice Guidelines 2013. Nankodo Co. Ltd.; 2013.</Citation></Reference><Reference><Citation>Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;2012(3):CD001447. doi:10.1002/14651858.CD001447.pub3</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD001447.pub3</ArticleId><ArticleId IdType="pmc">PMC7055506</ArticleId><ArticleId IdType="pubmed">22419278</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews JA, Jackson CE, Heiman-Patterson TD, Bettica P, Brooks BR, Pioro EP. Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(7-8):509-518. doi:10.1080/21678421.2020.1771734</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1771734</ArticleId><ArticleId IdType="pubmed">32573277</ArticleId></ArticleIdList></Reference><Reference><Citation>Takei K, Tsuda K, Takahashi F, Hirai M, Palumbo J. An assessment of treatment guidelines, clinical practices, demographics, and progression of disease among patients with amyotrophic lateral sclerosis in Japan, the United States, and Europe. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(sup1):88-97. doi:10.1080/21678421.2017.1361445</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1361445</ArticleId><ArticleId IdType="pubmed">28872912</ArticleId></ArticleIdList></Reference><Reference><Citation>Dystrophy Association Muscular. Highlights of the MDA U.S. Neuromuscular Disease Registry (2013-2016). Accessed October 26, 2022. mda.org/sites/default/files/MDA-Registry-Report-Highlights-Digital_9-2018.pdf.</Citation></Reference><Reference><Citation>Abe K, Aoki M, Tsuji S, et al. . Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505-512. doi:10.1016/S1474-4422(17)30115-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Berry JD, Ciepielewska M, et al. . Intravenous edaravone treatment in ALS and survival: an exploratory, retrospective, administrative claims analysis. EClinicalMedicine. 2022;52:101590. doi:10.1016/j.eclinm.2022.101590</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101590</ArticleId><ArticleId IdType="pmc">PMC9358426</ArticleId><ArticleId IdType="pubmed">35958519</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Macklin EA, Hendrix S, et al. . Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383(10):919-930. doi:10.1056/nejmoa1916945</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa1916945</ArticleId><ArticleId IdType="pmc">PMC9134321</ArticleId><ArticleId IdType="pubmed">32877582</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgos R, Breton I, Cereda E, et al. . ESPEN guideline clinical nutrition in neurology. Clin Nutr. 2018;37(1):354-396. doi:10.1016/j.clnu.2017.09.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2017.09.003</ArticleId><ArticleId IdType="pubmed">29274834</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, Hubbard J, Rudnicki SA, et al. . Survey of current enteral nutrition practices in treatment of amyotrophic lateral sclerosis. e-SPEN J. 2013;8(1):e25&#x2013;e28. doi:10.1016/j.clnme.2012.11.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnme.2012.11.003</ArticleId><ArticleId IdType="pmc">PMC4283833</ArticleId><ArticleId IdType="pubmed">25568837</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui F, Sun L, Xiong J, Li J, Zhao Y, Huang X. Therapeutic effects of percutaneous endoscopic gastrostomy on survival in patients with amyotrophic lateral sclerosis: a meta-analysis. PLoS One. 2018;13(2):e0192243. doi:10.1371/journal.pone.0192243</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0192243</ArticleId><ArticleId IdType="pmc">PMC5800689</ArticleId><ArticleId IdType="pubmed">29408898</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabor L, Gaziano J, Watts S, Robison R, Plowman EK. Defining swallowing-related quality of life profiles in individuals with amyotrophic lateral sclerosis. Dysphagia. 2016;31(3):376-382. doi:10.1007/s00455-015-9686-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00455-015-9686-2</ArticleId><ArticleId IdType="pmc">PMC4871719</ArticleId><ArticleId IdType="pubmed">26837611</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero-Gangonells E, Virgili-Casas MN, Dominguez-Rubio R, et al. . Evaluation of dysphagia in motor neuron disease. Review of available diagnostic tools and new perspectives. Dysphagia. 2021;36(4):558-573. doi:10.1007/s00455-020-10170-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00455-020-10170-7</ArticleId><ArticleId IdType="pubmed">32797289</ArticleId></ArticleIdList></Reference><Reference><Citation>Plowman EK, Tabor LC, Robison R, et al. . Discriminant ability of the eating assessment tool-10 to detect aspiration in individuals with amyotrophic lateral sclerosis. Neurogastroenterol Motil. 2016;28(1):85-90. doi:10.1111/nmo.12700</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.12700</ArticleId><ArticleId IdType="pmc">PMC4688134</ArticleId><ArticleId IdType="pubmed">26510823</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheney DM, Siddiqui MT, Litts JK, Kuhn MA, Belafsky PC. The ability of the 10-item eating assessment tool (EAT-10) to predict aspiration risk in persons with dysphagia. Ann Otol Rhinol Laryngol. 2015;124(5):351-354. doi:10.1177/0003489414558107</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0003489414558107</ArticleId><ArticleId IdType="pubmed">25358607</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol. 2006;5(2):140-147. doi:10.1016/s1474-4422(05)70326-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1474-4422(05)70326-4</ArticleId><ArticleId IdType="pubmed">16426990</ArticleId></ArticleIdList></Reference><Reference><Citation>Radunovic A, Annane D, Rafiq MK, Mustfa N. Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2013(3):CD004427. doi:10.1002/14651858.CD004427.pub3</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD004427.pub3</ArticleId><ArticleId IdType="pubmed">23543531</ArticleId></ArticleIdList></Reference><Reference><Citation>Newsom-Davis IC, Lyall RA, Leigh PN, Moxham J, Goldstein LH. The effect of non-invasive positive pressure ventilation (NIPPV) on cognitive function in amyotrophic lateral sclerosis (ALS): a prospective study. J Neurol Neurosurg Psychiatry. 2001;71(4):482-487. doi:10.1136/jnnp.71.4.482</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.71.4.482</ArticleId><ArticleId IdType="pmc">PMC1763518</ArticleId><ArticleId IdType="pubmed">11561031</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson CE, Lovitt S, Gowda N, Anderson F, Miller RG. Factors correlated with NPPV use in ALS. Amyotroph Lateral Scler. 2006;7(2):80-85. doi:10.1080/14660820500504587</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820500504587</ArticleId><ArticleId IdType="pubmed">16753971</ArticleId></ArticleIdList></Reference><Reference><Citation>Spittel S, Maier A, Kettemann D, et al. . Non-invasive and tracheostomy invasive ventilation in amyotrophic lateral sclerosis: utilization and survival rates in a cohort study over 12 years in Germany. Eur J Neurol. 2021;28(4):1160-1171. doi:10.1111/ene.14647</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14647</ArticleId><ArticleId IdType="pubmed">33210770</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe LF, Benditt JO, Aboussouan L, et al. . Optimal NIV Medicare access promotion: patients with thoracic restrictive disorders. Chest. 2021;160(5):e399-e408. doi:10.1016/j.chest.2021.05.075</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2021.05.075</ArticleId><ArticleId IdType="pmc">PMC8828932</ArticleId><ArticleId IdType="pubmed">34339688</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen-Flaschen J. Respiratory care for patients with amyotrophic lateral sclerosis in the US: in need of support. JAMA Neurol. 2021;78(9):1047-1048. doi:10.1001/jamaneurol.2021.2400</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2021.2400</ArticleId><ArticleId IdType="pubmed">34338729</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Brien D, Stavroulakis T, Baxter S, et al. . The optimisation of noninvasive ventilation in amyotrophic lateral sclerosis: a systematic review. Eur Respir J. 2019;54(3):1900261. doi:10.1183/13993003.00261-2019</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00261-2019</ArticleId><ArticleId IdType="pubmed">31273038</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceriana P, Surbone S, Segagni D, Schreiber A, Carlucci A. Decision-making for tracheostomy in amyotrophic lateral sclerosis (ALS): a retrospective study. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(7-8):492-497. doi:10.1080/21678421.2017.1317812</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1317812</ArticleId><ArticleId IdType="pubmed">28457142</ArticleId></ArticleIdList></Reference><Reference><Citation>Faull C, Rowe Haynes C, Oliver D. Issues for palliative medicine doctors surrounding the withdrawal of non-invasive ventilation at the request of a patient with motor neurone disease: a scoping study. BMJ Support Palliat Care. 2014;4(1):43-49. doi:10.1136/bmjspcare-2013-000470</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjspcare-2013-000470</ArticleId><ArticleId IdType="pubmed">24644770</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngandu H, Gale N, Hopkinson JB. Experiences of noninvasive ventilation in adults with hypercapnic respiratory failure: a review of evidence. Eur Respir Rev. 2016;25(142):451-471. doi:10.1183/16000617.0002-2016</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/16000617.0002-2016</ArticleId><ArticleId IdType="pmc">PMC9487549</ArticleId><ArticleId IdType="pubmed">27903667</ArticleId></ArticleIdList></Reference><Reference><Citation>de Almeida FEO, do Carmo Santana AK, de Carvalho FO. Multidisciplinary care in amyotrophic lateral sclerosis: a systematic review and meta-analysis. Neurol Sci 2021;42(3):911-923. doi:10.1007/s10072-020-05011-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-020-05011-2</ArticleId><ArticleId IdType="pubmed">33443670</ArticleId></ArticleIdList></Reference><Reference><Citation>Van den Berg JP, Kalmijn S, Lindeman E, et al. . Multidisciplinary ALS care improves quality of life in patients with ALS. Neurology. 2005;65(8):1264-1267. doi:10.1212/01.wnl.0000180717.29273.12</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000180717.29273.12</ArticleId><ArticleId IdType="pubmed">16247055</ArticleId></ArticleIdList></Reference><Reference><Citation>Londral A, Pinto A, Pinto S, Azevedo L, De Carvalho M. Quality of life in amyotrophic lateral sclerosis patients and caregivers: impact of assistive communication from early stages. Muscle Nerve. 2015;52(6):933-941. doi:10.1002/mus.24659</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.24659</ArticleId><ArticleId IdType="pubmed">25808635</ArticleId></ArticleIdList></Reference><Reference><Citation>Funke A, Spittel S, Grehl T, et al. . Provision of assistive technology devices among people with ALS in Germany: a platform-case management approach. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(5-6):342-350. doi:10.1080/21678421.2018.1431786</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1431786</ArticleId><ArticleId IdType="pubmed">29382225</ArticleId></ArticleIdList></Reference><Reference><Citation>Bock M, Duong YN, Kim A, Allen I, Murphy J, Lomen-Hoerth C. Cognitive-behavioral changes in amyotrophic lateral sclerosis: screening prevalence and impact on patients and caregivers. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17(5-6):366-373. doi:10.3109/21678421.2016.1165257</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2016.1165257</ArticleId><ArticleId IdType="pubmed">27043386</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>